| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.6 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |